ctDNA Informs Targeted Therapy Choice for Breast CancerFebruary 5th 2020
Patients with metastatic breast cancer who carry rare mutations identified by circulating tumor DNA responded to matched targeted therapies, according to results of the plasma-MATCH trial presented during the 2019 San Antonio Breast Cancer Symposium.
BCMA-Targeting Agents for the Treatment of Multiple Myeloma Take HoldFebruary 4th 2020
Across therapy vehicles, agents targeting the B-cell maturation antigen have emerged as promising potential therapies in the multiple myeloma treatment paradigm. Following the 2019 American Society of Hematology Annual Meeting & Exposition, experts reflect on what these new advances mean for the field of oncology care.